Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Unknown Primary × pemigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Cholangiocarcinoma 6 Carcinoma, Transitional Cell 5 Acrocephalosyndactylia 5 Neoplasm Metastasis 3 Gastrointestinal Neoplasms 3 Breast Neoplasms 3 Recurrence 2 Pancreatic Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor, Miscellaneous 1 Solid Tumor 1 Sarcoma 1 Oligodendroglioma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Myeloproliferative Disorders 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Locally Advanced Unresectable Gastric Cancer 1 Hematologic Neoplasms 1 Glioma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Eosinophilia 1

Interventions

Gemcitabine 8 Carboplatin 8 Paclitaxel 6 Capecitabine 4 Irinotecan 3 Bevacizumab 3 pembrolizumab 2 atezolizumab 2 Peripheral Blood Stem Cell Transplantation 2 Oxaliplatin 2 Filgrastim 2 Erlotinib Hydrochloride 2 Cisplatin 2 CP protocol 2 tegafur-gimeracil-oteracil 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 entrectinib 1 cobimetinib 1 belinostat 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1 Vemurafenib 1 Transurethral Resection of Prostate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡